Risk of reactivation of occult hepatitis B during immunotherapy in cancer treatment: myth, reality or new horizons?

Angioletta Lasagna; Valentina Zuccaro; Paolo Sacchi; Silvia Chiellino; Raffaele Bruno; Paolo Pedrazzoli

doi:10.2217/fon-2020-1196

Risk of reactivation of occult hepatitis B during immunotherapy in cancer treatment: myth, reality or new horizons?

Future Oncol. 2021 May;17(13):1577-1580. doi: 10.2217/fon-2020-1196. Epub 2021 Feb 16.

Authors

Angioletta Lasagna¹, Valentina Zuccaro², Paolo Sacchi², Silvia Chiellino¹, Raffaele Bruno^{2

3}, Paolo Pedrazzoli^{1

4}

Affiliations

¹ Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Viale Camillo Golgi 19, Pavia, Italy.
² Division of Infectious Diseases I, Fondazione IRCCS Policlinico San Matteo, Viale Camillo Golgi 19, Pavia, Italy.
³ Department of Clinical, Surgical, Diagnostic & Pediatric Sciences, University of Pavia, Viale Camillo Golgi 19, Pavia, Italy.
⁴ Department of Internal Medicine & Medical Therapy, University of Pavia, Viale Camillo Golgi 19, Pavia, Italy.

PMID: 33590770
DOI: 10.2217/fon-2020-1196

No abstract available

Keywords: Covalently closed circular DNA; OBI; Occult hepatitis B; cancer patients; immune checkpoint inhibitors; immunotherapy; prophylactic therapy; reactivation.

Publication types

Editorial

MeSH terms

Acute-On-Chronic Liver Failure / chemically induced
Acute-On-Chronic Liver Failure / epidemiology
Acute-On-Chronic Liver Failure / immunology*
Acute-On-Chronic Liver Failure / virology
Hepatitis B virus / drug effects
Hepatitis B virus / immunology
Hepatitis B, Chronic / epidemiology
Hepatitis B, Chronic / immunology*
Hepatitis B, Chronic / virology
Humans
Immune Checkpoint Inhibitors / adverse effects*
Immunocompromised Host
Latent Infection / chemically induced
Latent Infection / epidemiology
Latent Infection / immunology*
Latent Infection / virology
Neoplasms / drug therapy*
Neoplasms / immunology
Prevalence
Virus Activation / drug effects

Substances

Immune Checkpoint Inhibitors